Goldman Sachs Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins maintains a Buy rating on IDEAYA Biosciences (IDYA) but lowers the price target from $53 to $46.
May 13, 2024 | 3:50 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on IDEAYA Biosciences but reduces the price target from $53 to $46.
While the maintenance of a Buy rating by Goldman Sachs indicates continued confidence in IDEAYA Biosciences, the reduction in the price target could signal a tempered outlook on the stock's short-term price potential. This mixed signal might lead to neutral short-term price movement as investors weigh the positive endorsement against the lowered expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100